Cover Image
市場調查報告書

個體化癌症疫苗世界市場:市場機會與臨床創新展望

Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024

出版商 KuicK Research 商品編碼 447281
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
個體化癌症疫苗世界市場:市場機會與臨床創新展望 Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024
出版日期: 2018年04月24日 內容資訊: 英文 140 Pages
簡介

本報告針對個體化癌症疫苗市場臨床創新預測、提供個體化癌症疫苗概要與機制、生物標記相關性、開發、製造成本、近年技術進步成果與對市場的影響、市場促進、阻礙因素、今後市場動向預測分析。

第1章 個體化癌症疫苗:未來有潛力的癌症治療法

  • 癌症疫苗的可能性
  • 癌症疫苗:現在治療狀況考察

第2章 個體化癌症疫苗一般機制

  • 個體化癌症疫苗實際情況與角色
  • 使用中的個體化癌症疫苗
  • 藥物基因體學轉向基因多態性
  • 癌症藥物基因體學的體細胞突變

第3章 個體化疫苗與生物標記相關性

  • 藥物基因體學生物標記
  • 預後、預測生物標記
  • 免疫檢查點生物標記

第4章 個體化癌症疫苗製造工程、費用分析

  • 製造前費用分析
  • 個體化癌症疫苗製造費用分析
  • 個體化癌症疫苗:患者單人成本

第5章 個體化癌症疫苗市場:現在趨勢與今後動向

第6章 世界個體化癌症疫苗市場:癌症種類分類分析

  • 皮膚癌
  • 肺癌
  • 乳癌
  • 大腸癌
  • 白血病
  • 前列腺癌
  • 子宮頸癌
  • 腦瘤

第7章 個體化癌症疫苗開發的新收益來源、市場機會

第8章 五力分析:個體化癌症疫苗市場

  • 供應商交涉力
  • 買方交涉力
  • 可代替製品的威脅
  • 新加入企業的威脅
  • 現有企業競爭關係

第9章 個體化癌症疫苗市場促進因素

第10章 個體化癌症疫苗市場主要課題

第11章 世界個體化癌症疫苗市場未來展望

第12章 競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

“Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024” Report Highlights:

  • General Working Mechanism of Personalized Cancer Vaccine
  • Relevance of Biomarkers In Personalized Vaccines
  • Developmental Cost Analysis of a Personalized Cancer Vaccine
  • Advancements in the Personalized Cancer Vaccine
  • Personalized Cancer Vaccine Market Analysis by Cancer

Vaccines are therapeutics that helps protect body from disease. They unusually work by enhancing the ability of immune cells to recognize, target and destroy entities that might be harmful for the body. A Key immunotherapeutic product that has grabbed immense attention in the healthcare segment is the cancer vaccine; which is considered to be one of the most promising ways to treat, cure and prevent cancer.

Recent research proved that the genetic makeup of an individual has a significant impact on the overall therapeutic outcome of the administered therapeutic, which has led researchers to follow a more customized approach in vaccine manufacture to provide the best therapeutic output in patients suffering from a complex disease such as cancer. This customized approach would be more specifically targeted according to the patient's need which is bound to enhance the overall therapeutic outcome.

Currently there are two types of cancer vaccines available - preventive and therapeutic. Therapeutic vaccines treat an existing cancer by enhancing the body's natural immune system to recognize, target and destroy tumor cells. Provenge for prostate cancer is the only therapeutic vaccine approved for metastatic prostate cancer in the US.

Unlike cancer therapeutic vaccine, a preventive cancer vaccine is given to provide immunity against viruses that might cause cancer. The only preventative vaccines that have been successfully commercialized at a global level are the human papillomavirus vaccine and hepatitis B virus vaccine.

The cancer therapeutic segment is currently anticipated to be worth more than US$ 100 Billion. With rapid advancement in the immunotherapy segment, almost 60% of the market will be dominated by some immunotherapeutic product by 2024, thus forming the backbone of the global cancer therapy market. This presents an excellent opportunity for an innovative product such as the personalized cancer vaccine.

Genetic sequencing of patient's tumor cell for neo-antigen is a vital step in the manufacture of personalized cancer vaccine. About a decade ago, the cost for genetic sequencing for an individual was highly expensive, costing about US$ 300,000. Fortunately, the advancement in genetic sequencing techniques, emergence of advanced computing and artificial intelligence has made it a very affordable and faster process which is a major driving factor for the personalized cancer vaccine market.

The US is currently the leading market for personalized cancer vaccine, followed by the European Union. The early launch and impressive adoption of existing preventive and therapeutic cancer vaccine indicates that the US is bound to remain the dominant market for at least a decade. The involvement of regions like Japan, South Korea and China indicates it to be a competitive market in the future. Most of the cancer vaccines under development are focused on the treatment of deadly and highly prevalent cancers such as Melanoma, breast cancer, lung cancer, prostate cancer and Cervical Cancer.

KuicK Research Report on the personalized cancer vaccine market provides a detailed insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2024.

Table of Contents

1. Personalized Cancer Vaccine: Promising Cancer Therapeutics of the Future

  • 1.1. The Possibility of a Cancer Vaccine
  • 1.2. Cancer Vaccines - An Insight into its Current Clinical Status

2. General Working Mechanism of Personalized Cancer Vaccine

  • 2.1. Entities of A personalized Cancer Vaccine & Their Respective Roles
    • 2.1.1. Tumor Neo - Antigens
    • 2.1.2. Human Leukocyte Antigen
  • 2.2. Personalized Cancer Vaccine in Action
  • 2.3. Pharmacogenomics towards Genomic Polymorphism
  • 2.4. Somatic Mutations in Cancer Pharmacogenomics

3. Relevance of Biomarkers In Personalized Vaccines

  • 3.1. Pharmacogenomic Biomarkers
  • 3.2. Prognostic & Predictive Biomarkers
  • 3.3. Immune Checkpoint Biomarkers

4. Manufacturing Process & Cost Analysis of a Personalized Cancer Vaccine

  • 4.1. Pre - Manufacturing Cost Analysis
  • 4.2. Manufacturing Cost Analysis of Personalized Cancer Vaccine
    • 4.2.1. Capital Cost
    • 4.2.2. Cost of Raw Materials
    • 4.2.3. Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
    • 4.2.4. Factory & Administrative Overheads
    • 4.2.5. Filling & Packaging
  • 4.3. Personalized Cancer Vaccine Cost per Patient

5. Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment

  • 5.1. Breakthrough Research Improving the Outcome of Future Personalized Cancer Vaccine
  • 5.2. Rising Investments in the Personalized Cancer Vaccine Market
  • 5.3. Use of mRNA for the Development of Personalized Cancer Vaccine
  • 5.4. Collaborations & Ventures Ensure Stable Funding to the Personalized Cancer Vaccine Market
  • 5.5. Advancement in DNA Sequencing Technology to Drive the Personalized Cancer Vaccine Market

6. Global - Personalized Cancer Vaccine Market Analysis by Cancer Type

  • 6.1. Melanoma
  • 6.2. Lung Cancer
  • 6.3. Breast Cancer
  • 6.4. Colorectal Cancer
  • 6.5. Leukemia
  • 6.6. Prostate Cancer
  • 6.7. Cervical Cancer
  • 6.8. Glioblastoma (Brain Tumor)

7. New Avenues & Opportunities for Personalized Cancer Vaccine Development

  • 7.1. Commercial Insights into the Personalized Cancer Vaccine Pipeline
  • 7.2. Opportunities in the Emerging Market

8. Porter's Five Force Analysis of the Personalized Cancer Vaccine Market

  • 8.1. Bargaining Power of Suppliers
  • 8.2. Bargaining Power of Buyer
  • 8.3. Threats of Substitute Products
  • 8.4. Threat of New Entrants
  • 8.5. Rivalry Among the Existing Competitors

9. Driving Factors of the Personalized Cancer Vaccine Market

  • 9.1. Increasing Need for Personalized Cancer Vaccine Production
  • 9.2. Alarming Increase in the Number of Cancer Incidences
  • 9.3. Cancer Heterogenetic Environment
  • 9.4. High Level of Specificity
  • 9.5. Assistance from Government
  • 9.6. Improvement in Genome Sequencing Techniques
  • 9.7. Robust Clinical Pipeline Under Development

10. Major Challenges to the Personalized Cancer Vaccine Market

  • 10.1. Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
  • 10.2. Commercialization Challenges

11. Global Personalized Cancer Vaccine Market Future Outlook

12. Competitive Landscape

  • 12.1. Advaxis Inc.
  • 12.2. Avax Technologies
  • 12.3. BioNtech AG
  • 12.4. Celldex
  • 12.5. CureVac AG
  • 12.6. Genetech
  • 12.7. Genocea
  • 12.8. Gristone Oncology
  • 12.9. ISA Pharmaceuticals
  • 12.10. Merck
  • 12.11. Moderna Therapeutics
  • 12.12. Neon Therapeutics
  • 12.13. Personalis

List of Figures

  • Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
  • Figure 1-2: Advantages of Targeting Neo - Antigens in Cancer Vaccine Production
  • Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
  • Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
  • Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability's
  • Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
  • Figure 3-2: Roadmap of Development of Predictive Biomarkers
  • Figure 3-3: High Throughput Immune Assessment for Biomarker Discovery
  • Figure 4-1: General Overview of Personalized Cancer Vaccine Production
  • Figure 4-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
  • Figure 4-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
  • Figure 4-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
  • Figure 4-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
  • Figure 4-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
  • Figure 4-7: Gardasil - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
  • Figure 4-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
  • Figure 4-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
  • Figure 4-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
  • Figure 4-11: Gardasil - Manufacturing Cost per single Dose (US$), 2018
  • Figure 4-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
  • Figure 4-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
  • Figure 4-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
  • Figure 4-15: Gardasil & Gardasil 9 - Cost Analysis (US$), 2018
  • Figure 5-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
  • Figure 5-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
  • Figure 6-1: Alteration in CDKN2A Mechanism
  • Figure 6-2: Global - Melanoma & Non - Melanoma Cancer Incidence (000'), 2018
  • Figure 6-3: Global - Melanoma Prevalence by Region (%), 2018
  • Figure 6-4: Global - Lung Cancer Incidence (in 000'), 2018
  • Figure 6-5: Global - Lung Cancer Prevalence by Region (%), 2018
  • Figure 6-6: Global - Breast Cancer Incidence (000'), 2018
  • Figure 6-7: Global - Breast Prevalence by Region (%), 2018
  • Figure 6-8: Global - Colorectal Cancer Incidence (000') 2018
  • Figure 6-9: Global - Colorectal Cancer Market Size (%), 2018
  • Figure 6-10: Global - Leukemia Incidence (000'), 2018
  • Figure 6-11: Global - Leukemia Market Size (%), 2018
  • Figure 6-12: Global - Prostate Cancer Incidence (000'), 2018
  • Figure 6-13: Global - Prostate Cancer Prevalence by Region (%), 2018
  • Figure 6-14: Provenge - Cost Analysis (US$/Month)
  • Figure 6-15: Global - Cervical Cancer Incidence (000'), 2018
  • Figure 6-16: Global - Cervical Cancer prevalence by Region (%), 2018
  • Figure 7-1: Global - Oncology Market Size by Region (%), 2017
  • Figure 8-1: Porter's Five Force Analysis - Overview
  • Figure 9-1: Driving Factors of the Personalized Cancer Vaccine Market
  • Figure 9-2: Global - Most Common Types of Cancer by Prevalence, 2018
  • Figure 9-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
  • Figure 9-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
  • Figure 10-1: Scientific Limitations in Personalized Cancer Vaccine Development
  • Figure 11-1: Global - Gardasil Sales Forecast (US$ Billion), 2018 -2024
  • Figure 11-2: Cervarix - Future Sales Forecast (US$ Billion), 2018 - 2024
  • Figure 11-3: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2018 - 2024

List of Tables

  • Table 5-1: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
  • Table 5-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia
Back to Top